Close
  Indian J Med Microbiol
 

Figure 2: Retrospective versus prospective registration among subgroups. Numbers presented on each bar represents number of studies. (a) Type of study: post-marketing surveillance studies (n = 6: in which retrospective, n = 2; prospective, n = 4), bioavailability/bioequivalence (n = 1, prospective). (b) Study design: Nonrandomized studies (n = 16: in which retrospective, n = 13; prospective, n = 3), Other studies (n = 26: in which retrospective, n = 18; prospective, n = 8). (c) One study from 2013 enrolled both patients and healthy volunteers was registered retrospectively

Figure 2: Retrospective versus prospective registration among subgroups. Numbers presented on each bar represents number of studies. (a) Type of study: post-marketing surveillance studies (<i>n</i> = 6: in which retrospective, <i>n</i> = 2; prospective, <i>n</i> = 4), bioavailability/bioequivalence (<i>n</i> = 1, prospective). (b) Study design: Nonrandomized studies (<i>n</i> = 16: in which retrospective, <i>n</i> = 13; prospective, <i>n</i> = 3), Other studies (<i>n</i> = 26: in which retrospective, <i>n</i> = 18; prospective, <i>n</i> = 8). (c) One study from 2013 enrolled both patients and healthy volunteers was registered retrospectively